Mitochondria as a Target for Ophthalmic Disease

Time: 9:00 am
day: Day Two


  • Examining mitochondrial dysfunction as a key pathology in dry age-related macular degeneration, glaucoma, diabetic retinopathy and Fuch’s corneal endothelial dystrophy
  • Presenting preclinical data demonstrating elamipretide’s effect in models of ophthalmic disease
  • Showcasing clinical data showing that degree of baseline mitochondrial function may predict therapeutic response in patients with dry AMD
  • Demonstrating clinical data which shows how mitochondrial targeted therapeutics may not only slow disease progression, but also potentially improve visual function and/or visual field